Evaluation of Pulmonary Function Tests, Dyspnea Scores, and Antibody Levels at the Six-Month Follow-Up of Patients Hospitalized for COVID-19 Pneumonia

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Mar 13

PMID 38476506

Authors

Kadir Ozmen

Mehmet Meral

Bugra Kerget

Elif Yilmazel Ucar

Leyla Saglam

Murat Ozmen

Affiliations

Soon will be listed here.

Abstract

Background: Coronavirus disease 2019 (COVID-19) causes various signs and symptoms, especially lung involvement, during acute infection and in the long term. In this study, we evaluated the follow-up results of patients with chronic COVID-19 over a 24-week period.

Methods: The study included a total of 100 post-COVID-19 patients (confirmed by real-time polymerase chain reaction (PCR) of a nasopharyngeal swab) who presented to the post-COVID-19 outpatient clinic with chronic COVID-19 symptoms 12 weeks after diagnosis, between April and June 2021. All of the patients in the study had a history of hospitalization and were grouped based on the severity of the acute COVID-19 infection (moderate: group 1, severe: group 2).

Results: A comparison of pulmonary function test parameters at week 12 showed that forced expiratory volume (FEV1)%, forced vital capacity (FVC)%, diffusing capacity of the lungs for carbon monoxide (DLCO)%, and DLCO divided by the alveolar volume (DLCO/VA)% values were significantly lower in group 2 than in group 1 (p<0.001 for all). At week 24, only DLCO and DLCO/VA values were lower (<0.001 for both). The mean modified Medical Research Council (mMRC) dyspnea scores of groups 1 and 2 were 1.4 ± 0.9 and 2.8 ± 1.1 at 12 weeks and improved to 0.9 ± 0.6 and 1.6 ± 0.6 at 24 weeks, respectively. The groups' mMRC scores at 12 and 24 weeks differed significantly (p=0.001, p=0.02). There was no difference in levels of IgM and IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein between the groups at 12 or 24 weeks (p>0.05 for all).

Conclusion: Improvement in pulmonary function parameters and mMRC scores may take longer than 24 weeks, especially in patients with severe COVID-19. Our results indicated that the levels of IgM and IgG neutralizing antibodies did not differ between patients with moderate and severe illness at 12 or 24 weeks.

References

Fernandez-de-Las-Penas C, Palacios-Cena D, Gomez-Mayordomo V, Cuadrado M, Florencio L . Defining Post-COVID Symptoms (Post-Acute COVID, Long COVID, Persistent Post-COVID): An Integrative Classification. Int J Environ Res Public Health. 2021; 18(5). PMC: 7967389. DOI: 10.3390/ijerph18052621. View

Soriano J, Murthy S, Marshall J, Relan P, Diaz J . A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2021; 22(4):e102-e107. PMC: 8691845. DOI: 10.1016/S1473-3099(21)00703-9. View

Thomas M, Price O, Hull J . Pulmonary function and COVID-19. Curr Opin Physiol. 2021; 21:29-35. PMC: 7997144. DOI: 10.1016/j.cophys.2021.03.005. View

Kathirvel N . Post COVID-19 pandemic mental health challenges. Asian J Psychiatr. 2020; 53:102430. PMC: 7507979. DOI: 10.1016/j.ajp.2020.102430. View

Marklund E, Leach S, Axelsson H, Nystrom K, Norder H, Bemark M . Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders. PLoS One. 2020; 15(10):e0241104. PMC: 7577439. DOI: 10.1371/journal.pone.0241104. View

Liu G, Chen Y, Runa A, Liu J . Diagnostic performance of CO-RADS for COVID-19: a systematic review and meta-analysis. Eur Radiol. 2022; 32(7):4414-4426. PMC: 8961267. DOI: 10.1007/s00330-022-08576-y. View

Munari A, Gulart A, Santos K, Venancio R, Karloh M, Mayer A . Modified Medical Research Council Dyspnea Scale in GOLD Classification Better Reflects Physical Activities of Daily Living. Respir Care. 2017; 63(1):77-85. DOI: 10.4187/respcare.05636. View

Higgins R, Rawlings S, Case J, Lee F, Chan C, Barrick B . Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay. PLoS One. 2021; 16(3):e0247797. PMC: 7932143. DOI: 10.1371/journal.pone.0247797. View

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y . Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(16):2027-2034. PMC: 7184337. DOI: 10.1093/cid/ciaa344. View

10.

Dutta N, Mazumdar K, Gordy J . The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development. J Virol. 2020; 94(13). PMC: 7307180. DOI: 10.1128/JVI.00647-20. View

11.

Ayhanci T, Toptan H, Ozer Y, Uzar S, Enul H, Adiay C . [Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level]. Mikrobiyol Bul. 2022; 56(3):416-431. DOI: 10.5578/mb.20229704. View

12.

Komici K, Bianco A, Perrotta F, Dello Iacono A, Bencivenga L, DAgnano V . Clinical Characteristics, Exercise Capacity and Pulmonary Function in Post-COVID-19 Competitive Athletes. J Clin Med. 2021; 10(14). PMC: 8304629. DOI: 10.3390/jcm10143053. View

13.

Kerget B, Celik E, Kerget F, Aksakal A, Yilmazel Ucar E, Araz O . Evaluation of 3-month follow-up of patients with postacute COVID-19 syndrome. J Med Virol. 2022; 94(5):2026-2034. PMC: 9015610. DOI: 10.1002/jmv.27579. View

14.

Hsueh P, Huang L, Chen P, Kao C, Yang P . Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect. 2004; 10(12):1062-6. PMC: 7129952. DOI: 10.1111/j.1469-0691.2004.01009.x. View

15.

Fernandez-de-Las-Penas C, Ryan-Murua P, Rodriguez-Jimenez J, Palacios-Cena M, Arendt-Nielsen L, Torres-Macho J . Serological Biomarkers at Hospital Admission Are Not Related to Long-Term Post-COVID Fatigue and Dyspnea in COVID-19 Survivors. Respiration. 2022; 101(7):658-665. PMC: 9148886. DOI: 10.1159/000524042. View

16.

Kerget B, Cil G, Araz O, Alper F, Akgun M . When and how important is anti-fibrotic therapy in the post-COVID-19 period?. Bratisl Lek Listy. 2022; 123(9):653-6958. DOI: 10.4149/BLL_2022_105. View

17.

Walsh K, Jordan K, Clyne B, Rohde D, Drummond L, Byrne P . SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J Infect. 2020; 81(3):357-371. PMC: 7323671. DOI: 10.1016/j.jinf.2020.06.067. View

18.

Hotchin N, Read R, Smith D, Crawford D . Active Epstein-Barr virus infection in post-viral fatigue syndrome. J Infect. 1989; 18(2):143-50. DOI: 10.1016/s0163-4453(89)91150-x. View

19.

Du Toit A . Outbreak of a novel coronavirus. Nat Rev Microbiol. 2020; 18(3):123. PMC: 7073251. DOI: 10.1038/s41579-020-0332-0. View

20.

Raveendran A, Jayadevan R, Sashidharan S . Erratum to "Long COVID: An overview" [Diabetes Metabol. Syndr. Clin. Res. Rev. (2021) 869-875]. Diabetes Metab Syndr. 2022; 16(12):102660. PMC: 9637465. DOI: 10.1016/j.dsx.2022.102660. View